Different Immunosuppressive Treatment in iMN

Recruiting now · Phase 3

Conditions studied: Idiopathic Membranous Nephropathy

In brief

The primary objective of this study is to compare the 24 month remission of different immunosuppressive therapies in the treatment of idiopathic membranous nephropathy (iMN)

Key facts

Study ID

NCT04745728

Run by

Peking Union Medical College Hospital

People needed

200

Starts

2021-04-14

Expected to finish

2029-12-01

Last updated by the study team

2025-12-09

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• idiopathic membranous nephropathy
• Female, must be post-menopausal, sterile or have effective contraception
• must be off steroid or mycophenolate mofetil for >1 month and alkylating agents for or RTX> 6 months
• Angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) for ≥ 3 months with controlled blood pressure prior to beginning of immunosuppressive therapy or if patients are intolerant to ACEI/ARB.
• proteinuria ≥4g/24h and decreased ≤ 50% from baseline

You may not qualify if…

• presence of active infection or a secondary cause of membranous nephropathy
• proteinuria associated with diabetic nephropathy
• pregnancy or breast feeding
• history of resistance to rituximab or alkylating agents or corticosteroid
• Patients who previously achieved remission after treatment of rituximab or alkylating agents but relapsed off rituximab or alkylating agents after 6 months are eligible.

Where it is running

• Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.